OVID - Ovid Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 587.45M
Enterprise Value 340.08M
Trailing P/E N/A
Forward P/E 1-1.57
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.93
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-0.75

Trading Information

Stock Price History

Beta (3Y Monthly) 2.27
52-Week Change 3-62.02%
S&P500 52-Week Change 32.59%
52 Week High 36.8200
52 Week Low 31.5300
50-Day Moving Average 32.0440
200-Day Moving Average 31.9650

Share Statistics

Avg Vol (3 month) 3304.98k
Avg Vol (10 day) 3194.7k
Shares Outstanding 538.69M
Float 15.26M
% Held by Insiders 141.41%
% Held by Institutions 125.99%
Shares Short (Aug 15, 2019) 4426.41k
Short Ratio (Aug 15, 2019) 42.95
Short % of Float (Aug 15, 2019) 41.84%
Short % of Shares Outstanding (Aug 15, 2019) 41.10%
Shares Short (prior month Jul 15, 2019) 4488.92k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-54.31%
Return on Equity (ttm)-98.95%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -53.43M
Net Income Avi to Common (ttm)-52.72M
Diluted EPS (ttm)-1.7820
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)47.36M
Total Cash Per Share (mrq)1.22
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)5.84
Book Value Per Share (mrq)1.17

Cash Flow Statement

Operating Cash Flow (ttm)-45.72M
Levered Free Cash Flow (ttm)-29.11M